Thromboxanes and ischaemic vascular disease.

No abstract is available for this paper.

• Publication year

  1982

• Venue

  Netherlands Journal of Medicine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 7035978
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Circulating Platelet Products in Unstable Angina Pectoris

  1981cited by this paper
• Severe bleeding associated with defective thromboxane synthetase.

  1980cited by this paper
• Thromboxane A2 in blood vessel walls and its physiological significance: relevance to thrombosis and hypertension.

  1980cited by this paper
• Bleeding due to vascular disorders.

  1980cited by this paper
• Ca2+ -calmodulin-dependent phosphorylation and platelet secretion

  1980cited by this paper
• Stimulation of phosphatidic acid production in platelets precedes the formation of arachidonate and parallels the release of serotonin.

  1979cited by this paper
• A dominant role of thromboxane formation in secondary aggregation of platelets

  1979cited by this paper
• Diglyceride lipase: a pathway for arachidonate release from human platelets.

  1979cited by this paper
• Clot Promoting Effect of Platelet-Vessel wall Interaction

  1979cited by this paper
• Monoclonal characteristics of organising arterial thrombi: Significance in the origin and growth of human atherosclerotic plaques.

  1979cited by this paper
• Lysophosphatidic acids. Influence on platelet aggregation and intracellular calcium flux.

  1979cited by this paper
• Independence of the cyclic AMP-lowering activity of thromboxane A2 from the platelet release reaction.

  1979cited by this paper
• Are phospholipases involved in platelet activation?

  1979cited by this paper
• Increased synthesis of prostaglandin endoperoxides and platelet hyperfunction in infants of mothers with diabetes mellitus.

  1979cited by this paper
• A structural requirement for the conversion of prostaglandin endoperoxides to thromboxanes

  1979cited by this paper
• Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties.

  1979cited by this paper
• Haemostatic function and platelet polyunsaturated fatty acids in Eskimos.

  1979cited by this paper
• Decreased vascular prostacyclin in juvenile-onset diabetes.

  1979cited by this paper
• Effects of all cis-5,8,11,14,17 eicosapentaenoic acid and PGH3 on platelet aggregation.

  1979cited by this paper
• [Phospholipase A2 activity in rat platelets].

  1979cited by this paper
• Phosphatidic and lysophosphatidic acid production in phospholipase C-and thrombin-treated platelets. Possible involvement of a platelet lipase.

  1978cited by this paper
• Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin.

  1978cited by this paper
• Hereditary abnormality of platelet aggregation attributable to nucleotide storage pool deficiency.

  1978cited by this paper
• Chemotactic activity of thromboxane B2, prostaglandins and their metabolites for polymorphonuclear leucocytes.

  1978cited by this paper
• Development of radioimmunoassay for thromboxane B2.

  1978cited by this paper
• Unbalanced prostaglandin synthesis and plasma factors in uraemic bleeding. A hypothesis.

  1978cited by this paper
• Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis.

  1978cited by this paper
• Clonal Markers in the Study of the Origin and Growth of Human Atherosclerotic Lesions

  1978cited by this paper
• Possible congenital defect in platelet thromboxane synthetase.

  1977cited by this paper
• Solubilization and resolution of thromboxane synthesizing system from microsomes of bovine blood platelets.

  1977cited by this paper
• THE DISTRIBUTION AND METABOLISM OF ARACHIDONIC ACID IN RABBIT PLATELETS DURING AGGREGATION AND ITS MODIFICATION BY DRUGS

  1977cited by this paper
• The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits. Smooth muscle cell proliferation and re-endothelialization.

  1977cited by this paper
• Levels of prostaglandins F2 alpha and E2 and thromboxane B2 in joint fluid in rheumatoid arthritis.

  1977cited by this paper
• Conversion of prostaglandin endoperoxides to C17‐hydroxy acids catalyzed by human platelet thromboxane synthase

  1977cited by this paper
• The von Willebrand Pig as a Model for Atherosclerosis Research

  1977cited by this paper
• Biosynthesis of prostaglandin D2. 1. Formation of prostaglandin D2 by human platelets.

  1977cited by this paper
• Prostacyclin (PGI2) and bleeding time in uremic patients.

  1977cited by this paper
• Purification and characterisation of prostaglandin endoperoxide synthetase from sheep vesicular glands.

  1977cited by this paper
• The influence of prostaglandin G2 on platelet ultrastructure and platelet secretion.

  1977cited by this paper
• Metabolism of [14C]arachidonic acid by human platelets.

  1976cited by this paper
• Direct evidence for intracellular divalent cation redistribution associated with platelet shape change.

  1976cited by this paper
• Thromboxanes: selective biosynthesis and distinct biological properties.

  1976cited by this paper
• The pathogenesis of atherosclerosis (first of two parts).

  1976cited by this paper
• Mechanism for irreversible self-deactivation of prostaglandin synthetase.

  1976cited by this paper
• Formation of prostagland in D2 during endoperoxide-induced platelet aggregation.

  1976cited by this paper
• On the formation and effects of thromboxane A2 in human platelets.

  1976cited by this paper
• Sodium arachidonate can induce platelet shape change and aggregation which are independent of the release reaction.

  1976cited by this paper
• Inhibition of Injury Induced Thromboatherosclerotic Lesions by Anti-Platelet Serum in Rabbits

  1976cited by this paper
• Polymorphonuclear leukocytes produce thromboxane A2-like activity during phagocytosis.

  1976cited by this paper
• Malondialdehyde formation as an indicator of prostaglandin production by human platelets.

  1976cited by this paper
• The pathogenesis of atherosclerosis (second of two parts).

  1976cited by this paper
• Thrombin-induced oxygen consumption, malonyldialdehyde formation and serotonin secretion in human platelets.

  1976cited by this paper
• Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis.

  1976cited by this paper
• The influence of phospholipase A2 on prostaglandin production in platelets.

  1976cited by this paper
• Characterization of the Fawn-Hooded Rat as a Model for Hemostatic Studies

  1975cited by this paper
• Acetylation of prostaglandin synthase by aspirin.

  1975cited by this paper
• Clonal characteristics of fibrous plaques and fatty streaks from human aortas.

  1975cited by this paper
• Physiological role of an endoperoxide in human platelets: hemostatic defect due to platelet cyclo-oxygenase deficiency.

  1975cited by this paper
• Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.

  1975cited by this paper
• Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins.

  1974cited by this paper
• A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro.

  1974cited by this paper
• Evidence for a Monoclonal Origin of Human Atherosclerotic Plaques and Some Implications

  1974cited by this paper
• Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets.

  1974cited by this paper
• Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis.

  1973cited by this paper
• Induction of experimental arterial occlusive thrombi in rats.

  1973cited by this paper
• A new potential mediator of arterial thrombosis whose biosynthesis is inhibited by aspirin.

  1973cited by this paper
• Isolation and properties of intermediates in prostaglandin biosynthesis.

  1973cited by this paper
• Aortic fibrofatty type atherosclerosis from thrombus in normolipidemic rabbits.

  1973cited by this paper
• Evidence for a monoclonal origin of human atherosclerotic plaques.

  1973cited by this paper
• Hereditary defect in platelet function in rats.

  1972cited by this paper
• Effect of prostaglandin E 2 and aspirin on the secondary aggregation of human platelets.

  1972cited by this paper
• Characterization of human platelet vascular permeability-enhancing activity.

  1972cited by this paper
• [Relationship between coronary-artery thrombosis and myocardial infarction].

  1972cited by this paper
• Aspirin selectively inhibits prostaglandin production in human platelets.

  1971cited by this paper
• Indomethacin and aspirin abolish prostaglandin release from the spleen.

  1971cited by this paper
• Prostaglandins and Platelet Aggregation in Vivo

  1970cited by this paper
• Studies on lipid peroxides in platelets. I. Method of assay and effect of storage.

  1970cited by this paper
• Effect of acetylsalicylic acid, other nonsteroidal anti-inflammatory agents, and dipyridamole on human blood platelets.

  1970cited by this paper
• Release of Additional Factors in Anaphylaxis and its Antagonism by Anti-inflammatory Drugs

  1969cited by this paper
• Microthrombi and intimal thickening in bovine coronary arteries.

  1969cited by this paper
• The effect of salicylates on the hemostatic properties of platelets in man.

  1968cited by this paper
• Effects of salicylates on human platelets.

  1968cited by this paper
• Effect of prostaglandin E1 on platelet behaviour in vitro and in vivo.

  1967cited by this paper
• Coronary thrombosis and myocardial infarction.

  1966cited by this paper
• THE ENZYMATIC FORMATION OF PROSTAGLANDIN E2 FROM ARACHIDONIC ACID PROSTAGLANDINS AND RELATED FACTORS 32.

  1964cited by this paper
• Atherosclerotic metamorphosis of autologous pulmonary thromboemboli in the rabbit.

  1962cited by this paper
• Thrombosis as a factor in the pathogenesis of coronary atherosclerosis.

  1946cited by this paper

• VASCULAR OCCLUSION AH 23848 * : a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A 2

  2005cites this paper
• Cinnamophilin, a novel thromboxane A2 receptor antagonist, isolated from Cinnamomum philippinense.

  1994cites this paper
• [Changes in the platelet-vascular system of hemostasis in patients with ischemic heart disease and hypertension after the treatment].

  1989cites this paper
• [Prostaglandins and thromboxane in coronary arteriosclerosis].

  1987cites this paper
• AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2.

  1985cites this paper
• Nephrotic syndrome: A platelet hyperaggregability state

  1985cites this paper